Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc (NQ: CNTX )

2.150 +0.010 (+0.47%)
Streaming Delayed Price Updated: 9:46 AM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Context Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
From Context Therapeutics Inc.
Via GlobeNewswire
Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight
If you believe in chasing the winners higher, here are three hypergrowth stocks that may provide Nvidia-like gains. 
Via InvestorPlace
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them. 
Via InvestorPlace
CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024
CNTX stock results show that Context Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
--News Direct-- 
Via News Direct
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Announces $100 Million Private Placement
From Context Therapeutics Inc.
Via GlobeNewswire
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Important Regulatory Milestone Supports Next Phase of CTIM-76 Development 
From Context Therapeutics Inc.
Via GlobeNewswire
CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023
CNTX stock results show that Context Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 11, 2023
Via Benzinga
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr takes Proactive's Stephen Gunnion through progress with the company's lead program, CTIM-76. 
Via TheNewswire.com
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.